Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) kicked off on Friday, down -8.89% from the previous trading day, before settling in for the closing price of $15.97. Over the past 52 weeks, ARCT has traded in a range of $14.30-$45.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 301.31% over the past five years. While this was happening, its average annual earnings per share was recorded -33.73%. With a float of $24.37 million, this company’s outstanding shares have now reached $27.00 million.
Let’s look at the performance matrix of the company that is accounted for 176 employees. In terms of profitability, gross margin is 105.33%, operating margin of -55.8%, and the pretax margin is -58.49%.
Arcturus Therapeutics Holdings Inc (ARCT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arcturus Therapeutics Holdings Inc is 10.14%, while institutional ownership is 89.67%. The most recent insider transaction that took place on Oct 15 ’24, was worth 249,121. In this transaction Chief Scientific Officer & COO of this company sold 12,000 shares at a rate of $20.76, taking the stock ownership to the 435,334 shares. Before that another transaction happened on Oct 15 ’24, when Company’s Officer proposed sale 12,000 for $20.76, making the entire transaction worth $249,121.
Arcturus Therapeutics Holdings Inc (ARCT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -33.73% per share during the next fiscal year.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Trading Performance Indicators
Take a look at Arcturus Therapeutics Holdings Inc’s (ARCT) current performance indicators. Last quarter, stock had a quick ratio of 4.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.00, a number that is poised to hit -0.87 in the next quarter and is forecasted to reach -2.52 in one year’s time.
Technical Analysis of Arcturus Therapeutics Holdings Inc (ARCT)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) saw its 5-day average volume 0.44 million, a positive change from its year-to-date volume of 0.42 million. As of the previous 9 days, the stock’s Stochastic %D was 32.46%. Additionally, its Average True Range was 1.25.
During the past 100 days, Arcturus Therapeutics Holdings Inc’s (ARCT) raw stochastic average was set at 5.67%, which indicates a significant decrease from 8.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.95% in the past 14 days, which was lower than the 70.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.88, while its 200-day Moving Average is $21.09. Nevertheless, the first resistance level for the watch stands at $15.26 in the near term. At $15.98, the stock is likely to face the second major resistance level. The third major resistance level sits at $16.55. If the price goes on to break the first support level at $13.97, it is likely to go to the next support level at $13.40. Assuming the price breaks the second support level, the third support level stands at $12.68.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Key Stats
The company with the Market Capitalisation of 394.59 million has total of 27,087K Shares Outstanding. Its annual sales at the moment are 166,800 K in contrast with the sum of -29,730 K annual income. Company’s last quarter sales were recorded 41,670 K and last quarter income was -6,900 K.
